WINNIPEG, MANITOBA -- (MARKET WIRE) -- December 13, 2006 -- Miraculins Inc. (TSX VENTURE: MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, announced today that it does not intend to formalize its offer to combine with IBEX Technologies Inc.
